The ASX 200 (INDEXASX: XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) went down by 0.04% on Thursday.

Australian Dollar ($A) (AUDUSD): 70.17US cents

Dow Jones (DJI): down 0.51%

Oil (WTI): $US65.11 per barrel

Gold: $US1,278 per ounce

ASX Sharemarket News

In ASX sharemarket news, Flight Centre Travel Group Ltd (ASX: FLT) may see its share price come under pressure today with the travel business issuing a profit guidance downgrade.

The company said that its Australian leisure results have not recovered because of subdued trading conditions which is impacting total transaction value (TTV) measures.

Flight Centre also named a few other internal reasons for a decrease of profit.

Overall, the company is now expecting underlying profit before tax (PBT) for FY19 to be between $335 million to $360 million, which is below the $390 million to $420 million range previously guided. The mid-point of the new range, $347.5 million, would be a 10% decrease on FY18’s result.

***

Expert Interview: Magellan's Hamish Douglass

Hamish Douglass is one of Australia's top investors and founders, having co-founded Magellan - a near $9 billion business! Listen now on iTunes, SoundcloudCastbox, YouTube or Spotify.
***

Real estate giant Unibail-Rodamco-Westfield (ASX: URW) has revealed its March 2019 figures.

Tenant sales in its European shopping centres increased by 4.3% and footfall increased by 2.4%. US specialty sales per square foot grew by 5.3%. The business’ proportionate revenue increased by 70.2% to €939.6 million, largely due to the Westfield acquisition.

Since 7 June 2018 it has made €3.1 billion of disposals with an average premium above book value of 7.2%. In other words, it managed to sell assets at a higher price than what they were listed on the balance sheet for.

Popular Stories:

Biopharmaceutical business  Telix Pharmaceuticals Ltd (ASX: TLX) has published its fractionated prostate cancer therapy data with the results reportedly showing significant treatment benefit to patients.

The announcement said that a significant anti-tumour response is observed, particularly at the higher dosing levels.

ACCESS OUR NEW SMALL CAPS INVESTING REPORT!

After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite small-cap pocket rocket share ideas in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 300.

Access the free report by clicking here now or enter your email below! Absolutely no credit card or payment details required.



Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).

At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.